SPLICE BIO
Splice Bio is a gene therapy company based on technology developed in the Muir Lab at Princeton University. The company is developing novel gene therapies based on its proprietary intein platform technology to treat patients that suffer from incurable genetic diseases. The company’s platform has the potential to address two existing limitations of adeno-associated viruses (AAVs), both by increasing the size of the cargo gene that can be delivered and by expanding the range of tissues that can be targeted.
SPLICE BIO
Industry:
Biotechnology Life Science Medical Pharmaceutical
Founded:
2012-01-01
Address:
Barcelona, Catalonia, Spain
Country:
Spain
Website Url:
http://www.splice.bio
Total Employee:
11+
Status:
Active
Contact:
+34934020456
Total Funding:
51.7 M EUR
Technology used in webpage:
SPF Google Maps Microsoft Exchange Online Office 365 Mail Google Maps API Microsoft Azure DNS GoDaddy DNS
Similar Organizations
Aspen Neuroscience
Aspen Neuroscience is a biotechnology company that specializes in personalized cell therapies.
Faron Pharmaceuticals
Faron Pharmaceuticals is a biopharmaceutical company engaged in the biotechnology and medical research industry.
Novellus
Novellus is a biotechnology company working to develop engineered cellular medicines.
Current Advisors List
Board_member
2022-02-15
Board_member
Board_member
2022-02-15
Board_member
2020-09-01
Board_member
2022-02-15
Board_member
2022-02-15
Board_member
2020-09-01
Board_member
2022-02-15
Current Employees Featured
Miquel Vila- Perelló CEO-CSO and co-founder @ Splice Bio
CEO-CSO and co-founder
2020-09-01
Silvia Frutos CTO & Co-Founder @ Splice Bio
CTO & Co-Founder
2020-09-01
Founder
Investors List
Novartis Venture Fund
Novartis Venture Fund investment in Series A - Splice Bio
Gilde Healthcare
Gilde Healthcare investment in Series A - Splice Bio
UCB Ventures
UCB Ventures investment in Series A - Splice Bio
Asabys Partners
Asabys Partners investment in Series A - Splice Bio
Ysios Capital
Ysios Capital investment in Series A - Splice Bio
New Enterprise Associates
New Enterprise Associates investment in Series A - Splice Bio
Asabys Partners
Asabys Partners investment in Venture Round - Splice Bio
Ysios Capital
Ysios Capital investment in Venture Round - Splice Bio
Criteria Venture Tech
Criteria Venture Tech investment in Series A - Splice Bio
Key Employee Changes
Official Site Inspections
http://www.splice.bio Semrush global rank: 8.49 M Semrush visits lastest month: 523
- Host name: cl2024092609001.dnssw.net
- IP address: 81.25.126.103
- Location: Spain
- Latitude: 40.4172
- Longitude: -3.684
- Timezone: Europe/Madrid
More informations about "Splice Bio"
Splice Bio - Crunchbase Company Profile & Funding
Splice Bio is a gene therapy company based on technology developed in the Muir Lab at Princeton University. The company is developing novel gene therapies based on its proprietary intein platform technology to treat patients that suffer …See details»
Pipeline - SpliceBio
Lead program in Stargardt disease. SpliceBio is developing several gene therapy programs aimed at treating genetic diseases by exploiting our proprietary Protein Splicing platform.Our lead …See details»
SpliceBio Company Profile 2024: Valuation, Funding & Investors
Dec 2, 2017 SpliceBio General Information Description. Operator of a biotechnology company intended to develop genetic medicines through Protein Splicing gene therapy. The company's …See details»
Splice Bio | Funding, Valuation & Investors | Finallot
Explore Splice Bio profile on Finallot for insights on its team, products, and industry - Splice Bio is a biotech company that develops gene therapies using proprietary intein platform technology. …See details»
SpliceBio Raises EUR 50M in Oversubscribed Series A financing to ...
SpliceBio’s platform is based on technology developed in the Muir Lab at Princeton University after more than 20 years of pioneering intein and protein engineering research. For additional …See details»
Splice Bio - Funding, Financials, Valuation & Investors - Crunchbase
How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised . Lead Investors . Feb 15, 2022: Series A - Splice …See details»
Splice Bio - Gilde Healthcare
Feb 16, 2022 Splice Bio is a biotech company based on intein technologies developed in the Muir Lab at Princeton University. They are working with their proprietary platform to address key limitations of current gene therapy …See details»
Startup Bags €50M Series A to Smash Gene Therapy …
Feb 16, 2022 With this new funding in hand, SpliceBio has firmly established its gene therapy focus and is creating a pipeline of treatments for genetic blindness conditions.SpliceBio’s lead program has its crosshairs on Stargardt disease, a …See details»
SpliceBio Raises EUR 50M in Oversubscribed Series A financing to ...
2022_02_10_Splice Bio financing_FINAL_EMBARGO.pdf 122.82 KB Download. Related events. ASEBIO · DIEGO DE LEÓN, Nº 49, 1º IZQDA, 28006 MADRID (ESPAÑA) TEL: +34 91 210 …See details»
SpliceBio Raises $57 Million to Advance Protein Splicing Platform …
Feb 16, 2022 Rare Daily Staff Spanish biotech SpliceBio completed an oversubscribed $57 million (€50 million) series A financing to […]See details»
Roche builds gene therapy portfolio with SpliceBio deal
Nov 24, 2024 Roche’s gene therapy unit Spark has added to its pipeline in inherited retinal diseases (IRDs) with a $216 million alliance with Spanish biotech SpliceBio.See details»
SpliceBio Appoints David Favre, D.V.M., Ph.D., as Chief …
Jun 20, 2023 Dr. Favre brings extensive experience in gene therapy, immunology and drug development; Appointment comes at a pivotal time of Company growth as it prepares for …See details»
Breaking barriers to gene therapies for childhood rare diseases
Nov 28, 2022 The majority of known rare genetic diseases affect children, and gene therapies could help them live normal lives. Miquel Vila-Perelló, CEO and co-founder of the Spanish …See details»
Splice Bio: gene therapies that reassemble large proteins in vivo
Feb 16, 2022 Barcelona-based Splice Bio S.L. won the backing of lead investors UCB Ventures and Ysios Capital in its new €50 million ($56.6 million) series A round, which arrives about 17 …See details»
UCB, Novartis and more pile into SpliceBio series A ... - Fierce …
Feb 16, 2022 SpliceBio has raised 50 million euros ($57 million) from a starry syndicate to tackle one of the biggest barriers in gene therapy. Armed with the series A funds, the Barcelona …See details»
Gilde Healthcare company SpliceBio enters $216 million Gene …
Oct 17, 2023 SpliceBio is eligible to receive upfront, opt-in and milestone payments up to $216 million plus royalties Spark secures exclusive worldwide rights to SpliceBio’s proprietary …See details»
Protein Splicing - SpliceBio
Protein Splicing: pioneering a new gene therapy modality. Engineered split inteins lie at the core of SpliceBio’s platform, but we have developed additional proprietary technologies in-house …See details»
SpliceBio Enters Collaboration with Spark Therapeutics to Develop …
Oct 17, 2023 For additional information, please visit www.splice.bio About Spark Therapeutics Spark Therapeutics is a fully integrated, commercial company dedicated to unlocking the …See details»
SpliceBio Nets $56M Financing for Novel Gene Delivery Platform
Feb 17, 2022 SpliceBio has completed an oversubscribed more than $56 million (€50 million) series A financing which will enable the Spanish biotech to build a pipeline of Protein Splicing …See details»
SPLICER: a highly efficient base editing toolbox that enables in vivo ...
3 days ago Following treatment with ABEs, we observed that dual splice site targeting improved exon skipping compared to single splice site editing across all targets for multiple sets of …See details»